Mona Saraiya

Active 1998–2024

97
Papers
23,888
Citations
64
h-index
95
i10-index

Citations

Citations per year for Mona Saraiya1966: 1 citations1992: 1 citations1995: 1 citations1999: 1 citations2000: 2 citations2001: 1 citations2002: 4 citations2003: 11 citations2004: 10 citations2005: 15 citations2006: 20 citations2007: 47 citations2008: 102 citations2009: 102 citations2010: 91 citations2011: 104 citations2012: 117 citations2013: 147 citations2014: 171 citations2015: 151 citations2016: 158 citations2017: 157 citations2018: 129 citations2019: 578 citations2020: 648 citations2021: 907 citations2022: 708 citations2023: 454 citations2024: 728 citations2025: 313 citations2026: 13 citations1967–1991: no citations, so these years are not shown1993–1994: no citations, so these years are not shown1996–1998: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,371 citing papers, 32.1% of this breakdownChina: 768 citing papers, 10.4% of this breakdownUnited Kingdom: 362 citing papers, 4.9% of this breakdownCanada: 251 citing papers, 3.4% of this breakdownIndia: 224 citing papers, 3% of this breakdownAustralia: 216 citing papers, 2.9% of this breakdownItaly: 205 citing papers, 2.8% of this breakdownFrance: 200 citing papers, 2.7% of this breakdownGermany: 189 citing papers, 2.6% of this breakdownSpain: 161 citing papers, 2.2% of this breakdownNetherlands: 141 citing papers, 1.9% of this breakdownBelgium: 114 citing papers, 1.5% of this breakdown
0%32.1%Other 29.6%

Fields

  • Medicine78.1%
  • Biochemistry, Genetics and Molecular Biology8.5%
  • Social Sciences2.7%
  • Immunology and Microbiology2.6%
  • Computer Science1.9%
  • Health Professions1.7%
  • Other4.5%

Topics

  • Cervical Cancer and HPV Research19.1%
  • Global Cancer Incidence and Screening6.2%
  • Endometrial and Cervical Cancer Treatments4.9%
  • Head and Neck Cancer Studies4.5%
  • Vaccine Coverage and Hesitancy4.1%
  • Hepatitis B Virus Studies2.8%
  • Other58.4%

Coauthors

All papers

Open in search
  1. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis

    Authors: , , , , , , - The Lancet Global Health 2019 cited by 4,135

  2. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors

    Authors: , , , , , , , , , , , , , - Journal of Lower Genital Tract Disease 2020 cited by 1,342

  3. The IARC Perspective on Cervical Cancer Screening

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Béatrice Lauby-Secretan - New England Journal of Medicine 2021 cited by 340

  4. US Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV Vaccines

    Authors: , , , , , , , , , , , , , , , , - JNCI Journal of the National Cancer Institute 2015 cited by 762

  5. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices.

    Authors: , , , , , , , - 2015 cited by 1,061

  6. Trends in Human Papillomavirus–Associated Cancers — United States, 1999–2015

    Authors: , , , , , - MMWR Morbidity and Mortality Weekly Report 2018 cited by 518

  7. Human Papillomavirus–Attributable Cancers — United States, 2012–2016

    Authors: , , , , , - MMWR Morbidity and Mortality Weekly Report 2019 cited by 396

  8. Human Papillomavirus–Associated Cancers — United States, 2008–2012

    Authors: , , , , , , , - MMWR Morbidity and Mortality Weekly Report 2016 cited by 878

  9. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: Background and Consensus Recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Timothy H. McCalmont, Hope K. Haefner, Kieron Leslie, Christopher M. Shea, Paul N. Staats, Joel M. Palefsky, Alice Lytwyn, Barbara Winkler, Jennifer M. Roberts, Terence J. Colgan, Levi S. Downs, Rodolfo Laucirica, Richard J. Zaino, Debra S. Heller, Jill Allbritton, Olga B. Ioffe, Nancy E. Joste, Teresa M. Darragh, J. Michael Berry, Oscar Lin, Mark L. Welton, Christopher N. Otis, David C. Wilbur, Mark H. Stoler, Joel S. Bentz, Christina S. Kong, Bradley J. Quade, Mary R. Schwartz, Ronald D. Luff, Ritu Nayar, Philip E. Castle, Máire A. Duggan, Francisco García, Ann Moriarty, Greg Niedt, Alicia Carter, Marc T. Goodman, Margaret B. Neal, Vijaya Reddy, Stanley J. Robboy, Mona Saraiya, Steven M. Silverberg, Susan E. Spires - Archives of Pathology & Laboratory Medicine 2012 cited by 1,001

  10. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP).

    Authors: , , , , , , , - 2014 cited by 906

  11. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

    Authors: , , , , , - 2007 cited by 1,891

  12. Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage Levels

    Authors: , , , , , , , , , , , , , , , , , - JNCI Journal of the National Cancer Institute 2013 cited by 997

  13. Assessing Impact of HPV Vaccination on Cervical Cancer Incidence among Women Aged 15–29 Years in the United States, 1999–2017: An Ecologic Study

    Authors: , , , , - Cancer Epidemiology Biomarkers & Prevention 2020 cited by 117

  14. Economic burden of skin cancer treatment in the USA: an analysis of the Medical Expenditure Panel Survey Data, 2012–2018

    Authors: , , , , , - Cancer Causes & Control 2022 cited by 73

  15. Worldwide burden of cervical cancer in 2008

    Authors: , , , , , , - Annals of Oncology 2011 cited by 1,147

  16. COVID-19 impact on screening test volume through the National Breast and Cervical Cancer early detection program, January–June 2020, in the United States

    Authors: , , , , , , , , , , , , , - Preventive Medicine 2021 cited by 144

  17. 2019 ASCCP Risk-Based Management Consensus Guidelines: Updates Through 2023

    Authors: , , , , , , , , , , , , , - Journal of Lower Genital Tract Disease 2023 cited by 46

  18. Summary of Current Guidelines for Cervical Cancer Screening and Management of Abnormal Test Results: 2016–2020

    Authors: , , , , , , - Journal of Women s Health 2021 cited by 80

  19. EUROGIN 2011 roadmap on prevention and treatment of HPV‐related disease

    Authors: , , , , , , , , , , , , , , , , , - International Journal of Cancer 2012 cited by 254

  20. Impact of COVID-19 on Cervical Cancer Screening Rates Among Women Aged 21–65 Years in a Large Integrated Health Care System — Southern California, January 1–September 30, 2019, and January 1–September 30, 2020

    Authors: , , , , , , , , , , - MMWR Morbidity and Mortality Weekly Report 2021 cited by 167

  21. Risk-Based Cervical Consensus Guidelines: Methods to Determine Management if Less Than 5 Years of Data Are Available

    Authors: , , , , , , , , , , , - Journal of Lower Genital Tract Disease 2022 cited by 20

  22. Population-based cancer screening programmes in low-income and middle-income countries: regional consultation of the International Cancer Screening Network in India

    Authors: , , , , , , , , , , , , , - The Lancet Oncology 2018 cited by 96

  23. Cervical Precancers and Cancers Attributed to HPV Types by Race and Ethnicity: Implications for Vaccination, Screening, and Management

    Authors: , , , , , , , , , , , , , , - JNCI Journal of the National Cancer Institute 2022 cited by 30

  24. Cervical cancer survival in the United States by race and stage (2001‐2009): Findings from the CONCORD‐2 study

    Authors: , , , , , , , - Cancer 2017 cited by 114